Acquired coagulation-factor inhibitors

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Acquired coagulation inhibitors are antibodies that reduce the activity of a clotting factor or interfere with a phospholipid-dependent assay. Acquired haemophilia A, an autoantibody to factor VIII, is the clinically dominant bleeding disorder. It often arises without a recognised cause, but associations include the postpartum period, autoimmune disease, solid or haematological cancer and selected medicines. Unlike congenital haemophilia, there is no lifelong pedigree, haemarthrosis is less typical, and extensive skin, soft-tissue, gastrointestinal, genitourinary and retroperitoneal bleeding predominates.

The classic screen is a newly prolonged isolated APTT. Sample contamination and anticoagulants must be excluded. Mixing patient plasma with normal plasma tests whether missing factor is replaced: failure to correct, particularly after incubation, suggests an inhibitor. Confirm with factor VIII activity and a Nijmegen-modified Bethesda titre. Lupus anticoagulant can create non-correction and interfere with one-stage factor assays, so chromogenic methods and specialist interpretation may be required. A normal PT does not make bleeding safe.

Management has two parallel goals. First, stop clinically important bleeding using a bypassing agent or recombinant porcine factor VIII. Response is clinical: bleeding slows, haemoglobin stabilises, pain and swelling improve and imaging stops progressing. APTT does not monitor bypassing therapy. Second, suppress autoantibody production. Corticosteroids alone or combined with rituximab or cyclophosphamide are selected from FVIII, titre, frailty, infection, cancer and reproductive context. Infection prophylaxis and surveillance must begin with the regimen.

Not every inhibitor behaves like acquired haemophilia. Lupus anticoagulant usually accompanies thrombosis or no symptoms; rare factor V inhibitors can prolong both PT and APTT; factor XIII inhibitors may cause severe bleeding despite normal routine tests. The bleeding phenotype and deficient factor guide treatment. Once remission occurs, follow factor VIII and APTT for relapse, treat an underlying cancer or autoimmune disease, and revisit anticoagulation or thromboprophylaxis that was withheld during bleeding.

Key points

Suspect acquired haemophilia A in new extensive bruising, soft-tissue, mucosal, postpartum or postoperative bleeding with no lifelong history and an isolated prolonged APTT.
First-line laboratory assessment is FBC, PT, APTT, fibrinogen, thrombin time, medicine and sample review, followed urgently by immediate and incubated mixing, factor VIII activity and Nijmegen Bethesda inhibitor titre.
A mixing study that fails to correct after incubation supports a time-dependent inhibitor, but anticoagulants and lupus anticoagulant can confound it; interpret with the specialist laboratory.
Clinical bleeding severity, site and haemoglobin trajectory determine treatment urgency; inhibitor titre and factor VIII level do not reliably predict how severely a patient will bleed.
Preferred haemostatic options for significant acquired haemophilia bleeding are recombinant activated factor VII, activated prothrombin-complex concentrate or recombinant porcine factor VIII, selected by expertise and monitoring capability.
Recombinant factor VIIa is commonly 90 micrograms/kg intravenously every 2–3 hours initially; activated PCC is 50–100 units/kg every 8–12 hours, never exceeding 200 units/kg/day.
Begin inhibitor-eradication therapy promptly after diagnosis, but individualise corticosteroid alone versus combination treatment because frailty and infection risk can outweigh faster remission.
Minimise venepuncture and invasive procedures, avoid intramuscular injections, monitor haemoglobin and bleed sites closely, and reassess need for VTE prophylaxis as factor VIII recovers.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Autoantibody to factor VIII

Acquired haemophilia A is caused by a neutralising autoantibody, often in older adults, postpartum patients or people with autoimmune disease, malignancy or medicines.

Other specific inhibitors

Autoantibodies to factors V, IX, XI or XIII are rarer and may follow surgery, bovine thrombin exposure, infection, autoimmune disease or remain idiopathic.

Non-specific phospholipid inhibition

Lupus anticoagulants prolong phospholipid-dependent tests and usually indicate thrombosis rather than bleeding, although hypoprothrombombinaemia or another defect can coexist.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Time-dependent factor neutralisation
Factor VIII autoantibodies show non-linear, temperature- and time-dependent inhibition, so an incubated mixing study may uncover failure to correct missed initially.
2
Unstable fibrin generation
Loss of factor VIII activity impairs intrinsic tenase and thrombin amplification, producing extensive subcutaneous and muscle bleeding after minor vascular injury.
3
Bypassing haemostasis
Recombinant activated factor VII and activated prothrombin-complex concentrate generate thrombin downstream of factor VIII, so clinical response guides dosing rather than APTT normalisation.
4
Immune eradication
Corticosteroid, rituximab or cytotoxic therapy suppresses autoantibody production over weeks, exposing predominantly older patients to infection before remission is achieved.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Skin and soft tissue

Large spontaneous ecchymoses, painful muscle swelling and persistent line or wound bleeding are more characteristic than recurrent childhood haemarthrosis.

Concealed blood loss

Falling haemoglobin, back, flank, abdominal or groin pain and femoral neuropathy suggest retroperitoneal or iliopsoas haemorrhage.

Postpartum onset

Bleeding may begin during late pregnancy or months after delivery and can recur if a prolonged APTT is not investigated.

Laboratory mismatch

An isolated prolonged APTT in a bleeding adult without anticoagulant exposure should trigger a same-day mixing and factor-inhibitor pathway.

Non-bleeding inhibitor

An incidentally prolonged APTT with thrombosis rather than haemorrhage may be lupus anticoagulant, which has fundamentally different management.

Red flags requiring action

Falling haemoglobin, hypotension, severe abdominal, back or groin pain, nerve deficit or tense swelling suggests concealed retroperitoneal or muscle haemorrhage and requires urgent imaging after haemostasis begins.
Postpartum bruising or bleeding with an isolated prolonged APTT may be acquired haemophilia even when delivery was initially uncomplicated and previous haemostasis was normal.
A new prolonged APTT must not be dismissed as lupus anticoagulant when the patient is bleeding; factor deficiency, heparin contamination and a time-dependent inhibitor require urgent distinction.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line: FBC, PT, APTT, fibrinogen and thrombin timeFirst stepFirst line
Why
Define the bleeding consequence and localise the laboratory defect while detecting DIC or anticoagulant contamination.
Interpretation and limitations
Acquired haemophilia typically has isolated APTT prolongation with normal PT and platelets. Low fibrinogen or multichannel abnormalities require an alternative or additional diagnosis.
02
Immediate and incubated mixing study
Why
Distinguish factor deficiency from a time-dependent inhibitor.
Interpretation and limitations
Sustained correction supports deficiency; failure after incubation supports factor VIII inhibition. Lupus anticoagulant and medicines can also prevent correction, so this is not a stand-alone diagnosis.
03
Confirmatory factor VIII and inhibitor titreConfirmatory
Why
Demonstrate the deficient factor and quantify neutralising antibody.
Interpretation and limitations
Use factor VIII activity and Nijmegen Bethesda units; chromogenic testing helps when lupus anticoagulant or emicizumab interferes. Clinical bleeding is not proportional to the titre.
04
Anticoagulant interference testing
Why
Prevent misdiagnosis from heparin, dabigatran or factor Xa inhibitors.
Interpretation and limitations
Review last doses and renal function and use thrombin time, anti-Xa or drug-removal methods validated by the laboratory; repeat uncontaminated peripheral sampling when needed.
05
Cause and complication screen
Why
Identify associated disease and quantify hidden bleeding before immunosuppression.
Interpretation and limitations
Use pregnancy history, autoimmune assessment, age-appropriate cancer evaluation, CT for suspected concealed haemorrhage, infection screen and baseline renal, liver, glucose and viral status.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Heparin or DOAC effect

Line contamination, unfractionated heparin and direct anticoagulants alter clotting and mixing tests; thrombin time, anti-Xa assays and medicine timing prevent false inhibitor diagnoses.

Congenital factor deficiency

A lifelong personal or family bleeding history and complete immediate correction on mixing support inherited deficiency rather than a new autoantibody.

Lupus anticoagulant

Persistent non-correction without bleeding, phospholipid dependence and thrombosis history favour lupus anticoagulant, but low factor VIII and a specific inhibitor must still be excluded.

DIC or liver disease

These usually affect PT and multiple factors and may lower fibrinogen or platelets, unlike the isolated APTT pattern typical of acquired haemophilia A.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01New isolated prolonged APTTExclude drug before inhibitorFirst stepA bleeding adult has no known congenital disorder and PT is relatively preserved.

1Repeat a correctly collected peripheral sample and review UFH, LMWH, DOAC exposure, thrombin time and anti-Xa evidence.
2Request immediate and incubated mixing, factor VIII, IX and XI assays and lupus anticoagulant-informed interpretation with the coagulation laboratory.
3If factor VIII is low, quantify the inhibitor and contact the haemophilia centre immediately rather than waiting for every aetiological test.

02Clinically relevant bleedingBypass or replace promptlyBleeding is ongoing, causes haemoglobin fall, affects a critical site or requires urgent intervention.

1Use ABCDE, minimise punctures and obtain anatomical control while starting rFVIIa, activated PCC or recombinant porcine FVIII through specialist direction.
2Judge response from haemodynamics, haemoglobin, pain, swelling, external loss and repeat imaging; do not titrate bypassing agents to APTT.
3Switch strategy when response is inadequate and avoid simultaneous or rapidly sequential prothrombotic agents without haemophilia-centre oversight.

03Inhibitor eradicationIndividualise immune suppressionAcquired haemophilia A is confirmed and infection and frailty have been assessed.

1Choose corticosteroid alone for lower-risk biology or combine with rituximab or cyclophosphamide when predicted remission benefit justifies toxicity.
2Provide infection prevention, gastric, bone, glucose and reproductive safeguards suited to the regimen and actively screen for sepsis.
3Follow factor VIII and inhibitor titre until complete remission, taper treatment deliberately and continue surveillance because relapse can follow apparent recovery.

04Rare factor inhibitorMatch treatment to deficient factorPT, APTT or bleeding phenotype does not fit isolated factor VIII inhibition.

1Measure individual factors with inhibitor studies and exclude lupus anticoagulant and anticoagulant artefact through the specialist laboratory.
2Use site control, bypassing treatment, factor or platelet replacement according to the actual inhibited protein and laboratory response.
3Search for surgery, bovine thrombin, autoimmune disease, paraprotein, cancer or medicine association and treat it alongside eradication.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Bypasses factor VIII to generate thrombin for significant bleeding in acquired haemophilia A.

Recombinant activated factor VII

Give eptacog alfa 90 micrograms/kg by intravenous bolus every 2–3 hours until haemostasis is achieved, then lengthen the interval according to sustained clinical response under the haemophilia-centre protocol.

Monitor clinically rather than with APTT. Arterial and venous thrombosis can occur, especially in older adults with vascular disease or cancer; avoid unplanned combination with activated PCC and record every dose and response.

Provides activated and non-activated clotting proteins that bypass factor VIII during serious acquired-haemophilia bleeding.

Activated prothrombin-complex concentrate

Give 50–100 units/kg intravenously every 8–12 hours according to bleeding response, with a maximum total dose of 200 units/kg in 24 hours.

Do not exceed the daily ceiling. Monitor for DIC, myocardial, cerebral and venous thrombosis; use particular caution with emicizumab, sepsis, liver disease and recent sequential bypassing therapy.

Replaces factor VIII while avoiding many human FVIII autoantibodies and allows laboratory level monitoring.

Recombinant porcine factor VIII

Give an initial 200 units/kg intravenously for acquired haemophilia A, then measure porcine FVIII activity and individualise repeat doses and target levels to bleeding site and clinical response.

Check for anti-porcine inhibitor when available and monitor recovery closely because response varies. Thrombosis, hypersensitivity and excessive FVIII levels are possible; use only with specialist assay access.

Suppresses autoantibody production to restore endogenous factor VIII and achieve durable remission.

Prednisolone-based eradication

A common initial regimen is prednisolone 1 mg/kg orally once daily for up to 4–6 weeks with planned taper; add rituximab 375 mg/m² intravenously weekly for 4 doses or cyclophosphamide 1.5–2 mg/kg orally daily only after specialist risk selection.

Infection is a leading hazard. Screen viral status, protect bone and stomach where indicated, monitor glucose, blood pressure and FBC, adjust cyclophosphamide for age, renal function and fertility, and use pregnancy-compatible specialist alternatives.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Fatal concealed haemorrhage

Retroperitoneal, gastrointestinal, intracranial, airway and muscle bleeding can progress rapidly, while extensive skin bruising may underestimate total blood loss.

Compartment and nerve injury

Expanding muscle haematoma can compress peripheral nerves or threaten limb perfusion, requiring haemostatic control and careful surgical coordination.

Treatment-associated thrombosis

Bypassing agents and porcine factor can provoke arterial or venous thrombosis, especially in older adults with cancer, immobility or vascular disease.

Immunosuppression infection

Sepsis, neutropenia, hyperglycaemia and viral reactivation may cause more mortality than bleeding once initial haemostasis is secured.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During active bleeding, record haemodynamics, pain, swelling, neurological or limb findings, external loss and haemoglobin frequently; use repeat imaging for concealed sites when needed.
After each haemostatic strategy, document dose timing and objective response; APTT is not a response marker for recombinant factor VIIa or activated PCC.
During eradication, follow factor VIII, APTT and inhibitor titre at specialist intervals alongside FBC, renal and liver function, glucose and signs of infection.
Apply antimicrobial prophylaxis and viral-reactivation prevention according to the chosen steroid, rituximab or cytotoxic regimen and local immunosuppression policy.
After complete remission, continue factor VIII surveillance, educate about relapse symptoms and revisit withheld antithrombotic therapy once haemostasis and indication are reassessed.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Bleeding differs from congenital disease

Extensive skin and muscle haemorrhage in an older or postpartum person is more typical than recurrent childhood haemarthrosis.

Titre does not grade bleeding

A modest Bethesda titre can accompany life-threatening haemorrhage, so site and clinical trajectory drive haemostatic treatment.

Incubation reveals the inhibitor

Factor VIII autoantibodies may initially appear partly corrected but neutralise factor during a two-hour incubation at body temperature.

Bypassing tests stay abnormal

Successful rFVIIa or activated PCC treatment can stop bleeding without normalising APTT, making bedside and imaging response essential.

Infection can overtake bleeding

Once haemostasis is controlled, immunosuppression-related sepsis becomes a dominant preventable threat in a commonly frail population.

11Common pitfallsFrequent interpretation and management errors.

01
Ignoring an isolated prolonged APTT in a bleeding patient.
02
Calling non-correction lupus anticoagulant without factor assays.
03
Delaying haemostasis until the Bethesda titre returns.
04
Monitoring bypassing therapy by normalisation of APTT.
05
Combining bypassing agents casually and causing thrombosis.
06
Starting immunosuppression without infection and frailty safeguards.